WO2016145269A1 - Formes solides de lédipasvir et procédés pour la préparation de lédipasvir - Google Patents

Formes solides de lédipasvir et procédés pour la préparation de lédipasvir Download PDF

Info

Publication number
WO2016145269A1
WO2016145269A1 PCT/US2016/021905 US2016021905W WO2016145269A1 WO 2016145269 A1 WO2016145269 A1 WO 2016145269A1 US 2016021905 W US2016021905 W US 2016021905W WO 2016145269 A1 WO2016145269 A1 WO 2016145269A1
Authority
WO
WIPO (PCT)
Prior art keywords
ledipasvir
theta
degrees
crystalline form
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/021905
Other languages
English (en)
Inventor
Mohammad Mahboob ALAM
Judith Aronhime
Vinod Kumar Kansal
Siva Rama Krishna MUPPALLA
Anantha Rajmohan MUTHUSAMY
Dnyaneshwar Kondibhau NIGHOT
Ghanshyam PANDEY
Pramod Kadappa SHINDE
Amit Kumar TANEJA
Rengasamy Vadivelan
Sanjay Lakhabhai Vasoya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceuticals International GmbH
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals International GmbH, Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceuticals International GmbH
Publication of WO2016145269A1 publication Critical patent/WO2016145269A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • the present disclosure encompasses solid state forms of Ledipasvir, pharmaceutical compositions thereof and processes for preparation of Ledipasvir.
  • Ledipasvir is a hepatitis C virus (HCV) NS5A inhibitor. It is a component of the fixed-dose combination HARVONI® and is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.
  • HCV chronic hepatitis C
  • Ledipasvir is described in US 8,088,368. Solid state forms of Ledipasvir are described in WO 2013/184698, CN 104961733 and CN 105237517. Solid dispersions comprising Ledipasvir are described in WO 2014/120982.
  • WO 2014/120981 describes pharmaceutical compositions that comprise an effective amount of Ledipasvir, wherein the Ledipasvir is substantially amorphous, and an effective amount of sofosbuvir, wherein the sofosbuvir is substantially crystalline.
  • WO 2013/101550 describes a solid composition comprising an HCV inhibitor. Processes for preparation of Ledipasvir were described in US 8088368, WO 2013/184702 and in J. Med Chem. 2014, 57 (5), pp 2033-2046.
  • Polymorphism the occurrence of different crystalline forms, is a property of some molecules and molecular complexes.
  • a single molecule may give rise to a variety of polymorphs having distinct crystal structures and physical properties like melting point, thermal behaviors (e.g. measured by thermogravimetric analysis - "TGA”, or differential scanning calorimetry - “DSC”), X-ray diffraction pattern, infrared absorption fingerprint, and solid state ( 1 C) NMR spectrum.
  • TGA thermogravimetric analysis -
  • DSC differential scanning calorimetry -
  • Different salts and solid state forms (including solvated forms) of an active pharmaceutical ingredient may possess different properties. Such variations in the properties of different salts and solid state forms and solvates may provide a basis for improving formulation, for example, by facilitating better processing or handling characteristics, changing the dissolution profile in a favorable direction, or improving stability (polymorph as well as chemical stability) and shelf-life. These variations in the properties of different salts and solid state forms may also offer improvements to the final dosage form, for instance, if they serve to improve bioavailability. Different salts and solid state forms and solvates of an active pharmaceutical ingredient may also give rise to a variety of polymorphs or crystalline forms, which may in turn provide additional opportunities to assess variations in the properties and characteristics of a solid active pharmaceutical ingredient.
  • New solid state forms and solvates of a pharmaceutical product may yield materials having desirable processing properties, such as ease of handling, ease of processing, storage stability, and ease of purification or as desirable intermediate crystal forms that facilitate conversion to other polymorphic forms.
  • New solid state forms of a pharmaceutically useful compound can also provide an opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for formulation optimization, for example by providing a product with different properties, e.g., a different crystal habit, higher crystallinity, or polymorphic stability, which may offer better processing or handling characteristics, improved dissolution profile, or improved shelf-life (chemical/physical stability). For at least these reasons, there is a need for additional solid state forms (including solvated forms) of Ledipasvir.
  • WO 2013/184698 reports that the acetone solvate offers significant impurity purging capability in that the reaction mixture with 96-97.5% AN before crystallization was upgraded to -99.6% AN when Form I was isolated.
  • WO 2014/120982 describes preparation of solid dispersions from the acetone solvate. Use of solvates as starting material for preparation of the final dosage form requires monitoring the residual solvent content in the final dosage form. Further, the known synthetic processes have several drawbacks such as lower overall yield, use of column chromatography and use of toxic and costly solvents.
  • the present disclosure provides solid state forms of Ledipasvir, processes for preparation thereof, and pharmaceutical compositions thereof. These solid state forms can be used to prepare other solid state forms of Ledipasvir, Ledipasvir salts and their solid state forms.
  • the present disclosure provides solid state forms of Ledipasvir for use in the preparation of pharmaceutical compositions of Ledipasvir.
  • the present disclosure also encompasses the use of the Ledipasvir solid state forms of the present disclosure for the preparation of pharmaceutical compositions of Ledipasvir.
  • the present disclosure comprises processes for preparing the above mentioned pharmaceutical compositions.
  • the processes comprise combining the Ledipasvir solid state forms with at least one pharmaceutically acceptable excipient.
  • the solid state forms and the pharmaceutical compositions of Ledipasvir of the present disclosure can be used as medicaments, particularly for the treatment of Hepatitis C.
  • the present disclosure also provides methods of treating Hepatitis C, comprising administering a therapeutically effective amount of a Ledipasvir solid state form of the present disclosure, or at least one of the above pharmaceutical compositions, to a subject suffering from Hepatitis C, or otherwise in need of the treatment.
  • the present disclosure also provides processes for preparation of Ledipasvir.
  • Figure 1 shows an X-ray powder diffractogram of Form A of Ledipasvir.
  • Figure 2 shows an X-ray powder diffractogram of Form B of Ledipasvir.
  • Figure 3 shows an X-ray powder diffractogram of Form C of Ledipasvir.
  • Figure 4 shows an X-ray powder diffractogram of Form D of Ledipasvir.
  • Figure 5 shows an X-ray powder diffractogram of Form E of Ledipasvir.
  • Figure 6 shows an X-ray powder diffractogram of Form F of Ledipasvir.
  • Figure 7 shows an X-ray powder diffractogram of Form III of Ledipasvir.
  • Figure 8 shows an X-ray powder diffractogram of Form G of Ledipasvir.
  • Figure 9 shows an X-ray powder diffractogram of Form H of Ledipasvir obtained by example 8.
  • Figure 10 shows an X-ray powder diffractogram of Form C of Ledipasvir
  • Figure 1 1 shows an X-ray powder diffractogram of Form J of Ledipasvir.
  • Figure 12 shows an X-ray powder diffractogram of Form K of Ledipasvir.
  • Figure 13 shows an X-ray powder diffractogram of Form L of Ledipasvir.
  • Figure 14 shows an X-ray powder diffractogram of Form M of Ledipasvir, obtained by procedure 1 of example 14.
  • Figure 15 shows an X-ray powder diffractogram of Form M of Ledipasvir, obtained by procedure 2 of example 14.
  • Figure 16 shows an X-ray powder diffractogram of Form N of Ledipasvir, obtained by procedure 1 of example 15.
  • Figure 17 shows an X-ray powder diffractogram of Form N of Ledipasvir, obtained by procedure 2 of example 15.
  • Figure 18 shows an X-ray powder diffractogram of Form O of Ledipasvir.
  • Figure 19 shows an X-ray powder diffraction of form H of Ledipasvir obtained by example 17.
  • Figure 20 shows an X-ray powder diffraction of Ledipasvir Premix
  • Figure 21 shows an X-ray powder diffraction of Ledipasvir Premix
  • Figure 22 shows an X-ray powder diffraction of Ledipasvir Premix
  • Figure 23 shows an X-ray powder diffraction of Ledipasvir Premix
  • Figure 24 shows an X-ray powder diffraction of Ledipasvir Premix
  • Figure 25 shows an X-ray powder diffraction of Ledipasvir Premix
  • Figure 26 shows an X-ray powder diffraction of Ledipasvir Premix
  • Figure 27 shows an X-ray powder diffraction of Ledipasvir Premix
  • Figure 28 shows an X-ray powder diffraction of Ledipasvir Premix
  • Figure 29 shows an X-ray powder diffraction of form P of Ledipasvir obtained by example 19.
  • Figure 30 shows an X-ray powder diffraction of Ledipasvir crystalline Premix obtained by procedure 1 of example 21.
  • Figure 31 shows an X-ray powder diffraction of Ledipasvir crystalline Premix obtained by procedure 2 of example 21.
  • Figure 32 shows an X-ray powder diffraction of Ledipasvir crystalline Premix obtained by procedure 3 of example 21.
  • Figure 33 shows an X-ray powder diffraction of Ledipasvir crystalline Premix obtained by procedure 4 of example 21.
  • Figure 34 shows an X-ray powder diffraction of Ledipasvir Premix
  • Figure 35 shows the Solid-state 13C NMR spectrum of form G
  • the present disclosure encompasses solid state forms of Ledipasvir. Solid state properties of Ledipasvir can be influenced by controlling the conditions under which the Ledipasvir is obtained in solid form. [0053] The present disclosure further encompasses novel processes for preparation of Ledipasvir.
  • WO2010/132601 discloses a process having a very low overall yield ( ⁇ 10%), and requiring the use of column chromatography for purification in several steps.
  • the process uses toxic and costly solvents such as 1 ,4-dioxane, DME (dimethoxy ethane ) and xylene, as well as hazardous chemicals like NBS and tributyl (1-ethoxy vinyl) stannane and HATU [1 - [Bis(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5-b]pyridinium 3-oxid
  • WO2013/184702 also involves the use of toxic and/or non-economical solvents such as 2-methoxy ethanol, t-amyl alcohol as well as non-economical reagents such as Bis(neopen ⁇ yl glycolato)diboron, potassium propionate and PdC12[(Pt-Bu)2Ph]2 and MePhos(2-dicyclohexylphosphino- 2"methylbiphenyl)
  • toxic and/or non-economical solvents such as 2-methoxy ethanol, t-amyl alcohol
  • non-economical reagents such as Bis(neopen ⁇ yl glycolato)diboron, potassium propionate and PdC12[(Pt-Bu)2Ph]2 and MePhos(2-dicyclohexylphosphino- 2"methylbiphenyl)
  • the processes of the present disclosure avoids use of hazardous or non-economical reagents and solvents, several intermediates are not required to be isolated and others can be directly isolated with high yield and/or with high purity. Therefore, the processes of the present disclosure can be adapted to production in an industrial scale, i.e., greater than 1 kilogram scale.
  • the process of the present disclosure provides Ledipasvir in overall high yield, of about 40%, and high quality, i.e. high chemical purity.
  • Ledipasvir which contains about 0.1 % or less, preferably about 0.08% or less, more preferably 0.05% or less of methyl (l-(6-(5-(7-(2-(2- ((methoxycarbonyl)valyl)-2-azabicyclo[2.2.1]heptan-l -yl)-lH-benzo[d]imidazol-6-yl)-9-oxo- 9H-fluoren-2-yl)-lH-imidazol-2-yl)-5-azaspiro[2.4]heptan-5-yl)-3-methyl-l-oxobutan-2- yl)carbamate (herein designated as "keto impurity”) as an impurity and is represented by the following structural formula:
  • Prior art ledipasvir/ledipasvir pharmaceutical compositions typically may contain quantities of the keto impurity.
  • the crystalline forms of Ledipasvir of the disclosure are substantially free of any other forms of Ledipasvir, or of specified polymorphic forms of Ledipasvir, respectively.
  • the solid state forms of the present disclosure contain about 20% (w/w) or less of polymorphs, or of a specified polymorph of Ledipasvir. According to some embodiments, the solid state forms of the present disclosure contain about 10% (w/w) or less, about 5% (w/w) or less, about 2% (w/w) or less, about 1% (w/w) or less, about 0.5% (w/w) or less, or about 0.2% (w/w) or less of polymorphs, or of a specified polymorph of Ledipasvir.
  • solid state forms of Ledipasvir of the present disclosure contain from about 1% to about 20% (w/w), from about 5% to about 20% (w/w), or from about 5% to about 10% (w/w) of any solid state forms or of a specified polymorph of Ledipasvir.
  • the crystalline forms of Ledipasvir of the present disclosure have advantageous properties selected from at least one of the following: chemical purity, flowability, solubility, dissolution rate, morphology or crystal habit, stability- such as chemical stability, thermal and/or mechanical stability with respect to polymorphic conversion, stability towards dehydration and/or storage stability, low content of residual solvent, a lower degree of hygroscopicity, flowability, and advantageous processing and handling characteristics such as compressibility, and bulk density.
  • a solid state form such as a crystal form or amorphous form, may be referred to herein as being characterized by graphical data "as depicted in” or "as
  • Such data include, for example, powder X-ray diffractograms and solid state NMR spectra.
  • the graphical data potentially provides additional technical information to further define the respective solid state form (a so-called "fingerprint") which cannot necessarily be described by reference to numerical values or peak positions alone.
  • the skilled person will understand that such graphical representations of data may be subject to small variations, e.g., in peak relative intensities and peak positions due to certain factors such as, but not limited to, variations in instrument response and variations in sample concentration and purity, which are well known to the skilled person.
  • a crystal form of Ledipasvir referred to herein as being characterized by graphical data "as depicted in” or “as substantially depicted in” a Figure will thus be understood to include any crystal forms of Ledipasvir characterized with the graphical data having such small variations, as are well known to the skilled person, in comparison with the Figure.
  • the modifier "about” should be considered as disclosing the range defined by the absolute values of the two endpoints. For example, the expression “from about 2 to about 4" also discloses the range “from 2 to 4.”
  • the term “about” may refer to plus or minus 10% of the indicated number and includes the indicated number. For example, “about 10%” may indicate a range of 9% to 11%, and “about 1” means from 0.9-1.1.
  • anhydrous in relation to crystalline forms of Ledipasvir, relates to a crystalline form of Ledipasvir which does not include any crystalline water (or other solvents) in a defined, stoichiometric amount within the crystal. Moreover, an “anhydrous” form would typically not contain more than about 1% (w/w), of either water or organic solvents as measured for example by TGA.
  • solvate refers to a crystal form that incorporates a solvent in the crystal structure.
  • the solvent is water, the solvate is often referred to as a "hydrate.”
  • the solvent in a solvate may be present in either a stoichiometric or in a non-stoichiometric amount.
  • the term "isolated" in reference to solid state forms of Ledipasvir of the present disclosure corresponds to a solid state form of Ledipasvir that is physically separated from the reaction mixture in which it is formed.
  • the XRPD measurements are taken using copper Ka radiation wavelength of about 1.5418 A.
  • HPLC analysis As used herein, unless stated otherwise, chemical purity (area percent) may be measured by HPLC analysis.
  • the HPLC analysis is carried out using a reversed phase silica gel column (e.g. C18 column) using UV detection at 215 nm. Any suitable eluent can be used to carry out the separation (preferably a mixture of
  • acetonitrile/isopropanol is used). Chemical purity may also be measured by wt%.
  • a thing e.g., a reaction mixture
  • room temperature or “ambient temperature”, often abbreviated as "RT.”
  • RT room temperature
  • room temperature is from about 20°C to about 30°C, or about 22°C to about 27°C, or about 25°C.
  • the amount of solvent employed in a chemical process may be referred to herein as a number of "volumes” or “vol” or “V.”
  • a material may be referred to as being suspended in 10 volumes (or 10 vol or 10V) of a solvent.
  • this expression would be understood to mean milliliters of the solvent per gram of the material being suspended, such that suspending a 5 grams of a material in 10 volumes of a solvent means that the solvent is used in an amount of 10 milliliters of the solvent per gram of the material that is being suspended or, in this example, 50 mL of the solvent.
  • v/v may be used to indicate the number of volumes of a solvent that are added to a liquid mixture based on the volume of that mixture. For example, adding solvent X (1.5 v/v) to a 100 ml reaction mixture would indicate that 150 mL of solvent X was added.
  • a process or step may be referred to herein as being carried out “overnight.” This refers to a time interval, e.g., for the process or step, that spans the time during the night, when that process or step may not be actively observed. This time interval is from about 8 to about 20 hours, or about 10-18 hours, typically about 16 hours.
  • reduced pressure refers to a pressure that is less than atmospheric pressure.
  • reduced pressure is about 10 mbar to about 50 mbar.
  • Halo means a halogeno group. Specifically, fluoro, chloro, bromo, or iodo. In preferred embodiments, “Halo” refers to chloro or bromo, and preferably bromo.
  • one pot process refers to a continuous process for preparing a desired product, in which penultimate product is converted to the desired product in the same vessel.
  • Protecting group refers to a grouping of atoms that when attached to a reactive functional group in a molecule masks, reduces or prevents reactivity of the functional group. Examples of protecting groups can be found in Green et al, “Protective Groups in Organic Chemistry", (Wiley ,2 nd ed. 1991) and Harrison et al, “Compendium of Synthetic Organic Methods", Vols. 1-8 (John Wiley and Sons, 1971-1996).
  • Representative amine protecting groups include, but are not limited to, those where the amine group is converted to carbamate and amide such as Fmoc, cbz, benzyl, trityl, Boc, trifluoroacetyl derivative, phthalic anhydride, succinic anhydride derivative.
  • Specific Surface area is defined in units of square meters per gram (m 2 /g). Preferably, Specific Surface area as referred to herein, is measured by nitrogen absorption analysis (more preferably by Micromeritics TriStar II Plus surface area and porosity analyzer).
  • Specific Surface area (SSA) of an active pharmaceutical ingredient may be affected by various factors. There is a general connection between Specific Surface Area and Particle Size Distribution (PSD); the smaller the Particle Size, the higher the Specific Surface Area. Additional factors affecting SSA are the particle shape, the particle porosity, and inter- particle binding forces known to create aggregation. Generally high SSA is correlated to greater dissolution and bioavailability.
  • the term "bulk density” designates the ratio between mass (weight) and bulk volume for the powder blend. Testing for bulk density is typically performed by determining the bulk volume and the weight of a dry powder in a graduated cylinder. The bulk volume in this case takes into consideration the volume of the powder as well as any void spaces that may exist. High bulk density is desirable for reducing shipping and packaging costs.
  • tapped density refers to a density measurement of a substance that has been tapped or vibrated, thus minimizing the volume of the substance by eliminating or minimizing the air trapped between particles.
  • the tapped density is obtained by mechanically tapping a graduated measuring cylinder or vessel containing the powder sample. After observing the initial powder volume or mass, the measuring cylinder or vessel is mechanically tapped and volume or mass readings are taken until little further volume or mass change is observed.
  • tapped density is measured by Jolting Volumeter STAV-II (Lengelsmann, AG, more preferably with dropping height 3 mm ⁇ 0.1 mm) and tap speed: 250/min ⁇ 15/min and measurement of volume after 1250 taps).
  • Carr's compressibility index (CI) and Hausner ratio (HR) are calculated according to the following equations - and provide a measure of the flow properties and compressability. where ptap is the tapped density and pbulk is the bulk density.
  • ledipasvir Premix refers to a co-precipitate of Ledipasvir with a pharmaceutically acceptable carrier, and optionally other pharmaceutically acceptable excipients.
  • a co-precipitate may be prepared by mixing Ledipasvir and a pharmaceutically acceptable carrier and optionally other pharmaceutically acceptable excipients in solvent(s) to form a mixture, and removing the solvent(s) from the mixture.
  • the mixture may be a solution (e.g. wherein the components are dissolved), or a suspension or dispersion (e.g. wherein none of the components are dissolved but form a suspension or dispersion, or wherein some but not all of the components are dissolved).
  • the term ledipasvir Premix refers to a coprecipitate of Ledipasvir with copovidone, and optionally other pharmaceutically acceptable excipients.
  • a co-precipitate of Ledipasvir can be prepared by mixing Ledipasvir and a pharmaceutically acceptable carrier and optionally other pharmaceutically acceptable excipients in solvent(s) to form a solution, and removing the solvent(s) from the solution.
  • a co-precipitate of Ledipasvir can be prepared by mixing Ledipasvir and a pharmaceutically acceptable carrier and optionally other pharmaceutically acceptable excipients in solvent(s) to form a mixture wherein the pharmaceutically acceptable carrier is dissolved and the Ledipasvir is substantially undissolved, and removing the solvent(s) from the mixture.
  • a co-precipitate of Ledipasvir can be prepared by mixing Ledipasvir and a pharmaceutically acceptable carrier and optionally other pharmaceutically acceptable excipients in solvent(s) to form a mixture wherein both the Ledipasvir and the pharmaceutically acceptable carrier form a suspension, and removing the solvent(s) from the mixture.
  • amorphous premix refers to a premix comprising substantially amorphous Ledipasvir.
  • an amorphous premix may be prepared dissolving Ledipasvir and a
  • crystalline premix refers to a premix comprising ledipasvir wherein the ledipasvir is in substantially crystalline form.
  • a crystalline premix can be prepared by mixing Ledipasvir and a pharmaceutically acceptable carrier and optionally other pharmaceutically acceptable excipients in solvent(s) to form a mixture wherein the pharmaceutically acceptable carrier is dissolved and wherein the Ledipasvir is substantially undissolved, and removing the solvent(s) from the mixture.
  • substantially amorphous is intended to mean greater than about 70%; or greater than about 75%; or greater than about 80%; or greater than about 85%; or greater than about 90%; or greater than about 95%, or greater than about 99% of the compound present in a composition is in amorphous form.
  • substantially crystalline is intended to mean that greater than about 70%; or greater than about 75%; or greater than about 80%; or greater than about 85%; or greater than about 90%; or greater than about 95%, or greater than about 99% of the compound is present in a composition is in crystalline form.
  • crystalline form III of Ledipasvir refers to a crystalline form which may be characterized by X-ray powder diffraction pattern as depicted in Figure 7.
  • the present disclosure comprises a crystalline form of Ledipasvir, designated form A, having an X-ray powder diffraction pattern substantially as depicted in Figure 1 , wherein form A is not an acetone solvate.
  • Crystalline form A of Ledipasvir may be further characterized by an X-ray powder diffraction pattern having peaks at 6.5, 9.0 and 12.5 degrees two theta ⁇ 0.2 degrees two theta.
  • crystalline form A of Ledipasvir may be characterized by an X-ray powder diffraction pattern having peaks at 6.5, 9.0 and 12.5 degrees two theta ⁇ 0.2 degrees two theta and the absence of peaks at 10.2, 19.8 and 23.8 degrees two theta ⁇ 0.1 degrees two theta.
  • form A of Ledipasvir is isolated.
  • the present disclosure comprises a crystalline form of Ledipasvir, designated form B, having an X-ray powder diffraction pattern substantially as depicted in Figure 2, wherein form B is not an acetone solvate.
  • Crystalline form B of Ledipasvir may be further characterized by X-ray powder diffraction pattern having peaks at 6.9, 9.6 and 13.5 degrees two theta ⁇ 0.2 degrees two theta.
  • crystalline form B of Ledipasvir may be characterized by an X-ray powder diffraction pattern having peaks at 6.9, 9.6 and 13.5 degrees two theta ⁇ 0.2 degrees two theta and the absence of a peak at 11.0 degrees two theta ⁇ 0.1 degrees two theta.
  • Crystalline form B of Ledipasvir may be a hydrate.
  • form B may contain from about 2% to about 6% of water by weight, preferably about 3 % of water by weight as measured by Karl Fischer titrator and TGA.
  • crystalline form B of Ledipasvir may be a mono to trihydrate.
  • form B of Ledipasvir is isolated.
  • the present disclosure relates to solid state form of Ledipasvir, preferably in crystalline form, wherein said form is a hydrate.
  • the present disclosure relates to solid state form of Ledipasvir, preferably in crystalline form, wherein said form contain from about 2% to about 6% of water, preferably about 3% of water by weight.
  • the present disclosure comprises a crystalline form of Ledipasvir, designated form C, characterized by X-ray powder diffraction pattern having peaks at 6.8, 8.8, 12.3 and 20.4 degrees two theta ⁇ 0.1 degrees two theta.
  • crystalline form C of Ledipasvir may be characterized by an X-ray powder diffraction pattern substantially as depicted in Figure 3 or in Figure 10.
  • Crystalline form C of Ledipasvir may be further characterized by X-ray powder diffraction pattern having peaks at 6.8, 8.8, 12.3 and 20.4 degrees two theta ⁇ 0.1 degrees two theta.
  • form C of Ledipasvir is isolated.
  • crystalline form C may be an acetone and cyclohexane solvate.
  • form C may contain from about 5 % to about 7 % of acetone and from about 2 % to about 5 % of cyclohexane, specifically, about 6 % of acetone and about 2.5% of cyclohexane by weight.
  • the present disclosure comprises a crystalline form of Ledipasvir, designated form D, characterized by X-ray powder diffraction pattern having peaks at 6.7, 12.3, 18.2 and 23.6 degrees two theta ⁇ 0.1 degrees two theta.
  • crystalline form D may be characterized by an X-ray powder diffraction pattern substantially as depicted in Figure 4.
  • form D can be characterized by a combination of these data.
  • form D of Ledipasvir is isolated.
  • the present disclosure comprises a crystalline form of Ledipasvir, designated form E, characterized by X-ray powder diffraction pattern having peaks at 8.7, 12.3, 18.2 and 22.6 degrees two theta ⁇ 0.1 degrees two theta.
  • form E is not a methyl ethyl ketone (MEK) solvate.
  • crystalline form E may be characterized by an X-ray powder diffraction pattern substantially as depicted in Figure 5.
  • Crystalline form E of Ledipasvir may be further characterized by X-ray powder diffraction pattern having peaks at 8.7, 12.3, 18.2 and 22.6 degrees two theta ⁇ 0.1 degrees two theta.
  • form E of Ledipasvir is isolated.
  • the present disclosure comprises a crystalline form of Ledipasvir, designated form F, characterized by X-ray powder diffraction pattern having peaks at 10.2, 12.3, 17.4 and 21.6 degrees two theta ⁇ 0.1 degrees two theta.
  • form F is not a methyl tert-butyl ether (MTBE) solvate.
  • crystalline form F may be characterized by an X-ray powder diffraction pattern substantially as depicted in Figure 6.
  • Crystalline form F of Ledipasvir may be further characterized by X-ray powder diffraction pattern having peaks at 10.2, 12.3, 17.4 and 21.6 degrees two theta ⁇ 0.1 degrees two theta.
  • form F of Ledipasvir is isolated.
  • the present disclosure comprises a crystalline form of Ledipasvir, designated form G, characterized by data selected from: an X-ray powder diffraction pattern substantially as depicted in Figure 8; an X-ray powder diffraction pattern having peaks at 7.3, 14.0, 19.5 and 20.4 degrees two theta ⁇ 0.1 degrees two theta and having no peaks at 3.9 and 12.7 degrees two theta ⁇ 0.1 degrees two theta; or any combination thereof.
  • Crystalline form G of Ledipasvir may be further characterized by an X-ray powder diffraction pattern having an additional peak at 26.6 degrees two theta ⁇ 0.1 degrees two theta.
  • crystalline form G of Ledipasvir may be characterized by data selected from: an X-ray powder diffraction pattern substantially as depicted in Figure 8; an X-ray powder diffraction pattern having peaks at 7.3, 9.5, 11.3, 12.1, 14.0, 19.5, 20.4 and 26.6 degrees two theta ⁇ 0.1 degrees two theta and having no peaks at 3.9 and 12.7 degrees two theta ⁇ 0.1 degrees two theta; or any combination thereof.
  • crystalline form G may be characterized by data selected from: an X-ray powder diffraction pattern having peaks at 8.7, 13.2, 14.6, 15.5, 17.2, 18.0, 23.1, 24.2, 24.9 and 26.6 degrees two theta ⁇ 0.1 degrees two theta.
  • Crystalline form G of Ledipasvir may be further characterized by an X-ray powder diffraction pattern having no peaks 3.2 and 12.7 degrees two theta ⁇ 0.1 degrees two theta.
  • crystalline form G may be characterized by data selected from: a solid state 13C NMR spectrum having peaks at 139.5, 137.7, 122.0 and 111.8 ppm ⁇ 0.2 ppm; a solid state 13C NMR spectrum having chemical shift differences between said characteristic peaks at 139.5, 137.7, 122.0 and 111.8 ppm ⁇ 0.2 ppm and a reference peak at 107.4 ppm ⁇ 0.2 ppm of 32.1, 30.3, 14.6 and 4.4 and ppm ⁇ 0.1 ppm , respectively; a solid state 13C NMR spectrum substantially as depicted in Figure 35; or any combination thereof
  • Crystalline form G of Ledipasvir may be further characterized by data selected from: a solid state 13C NMR spectrum with peaks at 61.5, 40.0, 38.4 and 25.4 ppm ⁇ 0.2 ppm; a solid state 13C NMR spectrum having chemical shift differences between said characteristic peaks at 61.5, 40.0, 38.4 and 25.4 ppm ⁇ 0.2 ppm and a reference peak at 107.4 ppm ⁇ 0.2 ppm of 45.9, 67.4, 69.0 and 82.0 and ppm ⁇ 0.1 ppm , respectively; or
  • Form G may be characterized by any one of the above embodiments or any combination thereof.
  • the form G may be an acetone solvate or an acetone and MDC solvate.
  • crystalline form G may be an acetone solvate.
  • Form G may contain from about 3 % to about 7 % of acetone, preferably about 5 % of acetone by weight.
  • Form G may contain from about 3 % to about 7 % of acetone and from about 1% to about 3% of MDC, preferably, about 5 % of acetone and about 2% MDC by weight.
  • form G of Ledipasvir is isolated.
  • Crystalline Form G of Ledipasvir may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g. by an X-ray powder diffraction pattern having peaks at 7.3, 14.0, 19.5 and 20.4 degrees two theta ⁇ 0.1 degrees two theta and having no peaks at 3.9 and 12.7 degrees two theta ⁇ 0.1 degrees two theta wherein form G is an acetone solvate.
  • the present disclosure comprises a crystalline form of Ledipasvir, designated form H, characterized by data selected from: an X-ray powder diffraction pattern substantially as depicted in Figure 9; an X-ray powder diffraction pattern substantially as depicted in Figure 19; X-ray powder diffraction pattern having peaks at 17.0, 19.0, 19.8 and 20.9 degrees two theta ⁇ 0.1 degrees two theta and having no peaks at 12.8 and 16.7 degrees two theta ⁇ 0.1 degrees two theta; or any combination thereof.
  • crystalline form H of Ledipasvir may be characterized by data selected from: an X-ray powder diffraction pattern substantially as depicted in Figure 9; an X-ray powder diffraction pattern substantially as depicted in Figure 19; X-ray powder diffraction pattern having peaks at 7.6, 9.0, 12.1 , 17.0 and 19.0 degrees two theta ⁇ 0.1 degrees two theta and having no peaks at 12.8 and 16.7 degrees two theta ⁇ 0.1 degrees two theta; or any combination thereof.
  • crystalline form H may be anhydrous.
  • form H of Ledipasvir is isolated.
  • Crystalline Form H of Ledipasvir may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g. by an X-ray powder diffraction pattern having peaks at 17.0, 19.0, 19.8 and 20.9 degrees two theta ⁇ 0.1 degrees two theta and having no peaks at 12.8 and 16.7 degrees two theta ⁇ 0.1 degrees two theta wherein form H is anhydrous.
  • the present disclosure comprises a crystalline form of Ledipasvir, designated form J.
  • Form J may be characterized by an X-ray powder diffraction pattern substantially as depicted in Figure 1 1.
  • Form J may be further characterized by an X- ray powder diffraction pattern having peaks at 7.2, 8.9, 12.2, 17.2, 18.0, 19.3, 20.8 and 21.3 degrees two theta ⁇ 0.2 degrees two theta.
  • crystalline form J may be a cyclohexane solvate. In certain embodiments, Form J may contain from about 2 % to about 7 % of cyclohexane by weight.
  • crystalline form J may be characterized by an X-ray powder diffraction pattern having peaks at 7.2, 8.9, 17.2, 18.0 and 19.3 degrees two theta ⁇ 0.1 degrees two theta wherein form J is a cyclohexane solvate.
  • form J of Ledipasvir is isolated.
  • the present disclosure comprises a crystalline form of Ledipasvir, designated form K.
  • Form K may be characterized by an X-ray powder diffraction pattern substantially as depicted in Figure 12.
  • Form K may be further characterized by an X- ray powder diffraction pattern having peaks at 5.4, 7.1, 11.2, 12.1, 13.8, 15.3, 20.1, 21.5 and 22.5 degrees two theta ⁇ 0.2 degrees two theta.
  • crystalline form K may be a cyclohexane solvate. In certain embodiments, Form K may contain from about 2 % to about 7 % of cyclohexane by weight.
  • crystalline form K may be characterized by X-ray powder diffraction pattern having peaks at 5.4, 7.1, 11.2, 13.8 and 15.3 degrees two theta ⁇ 0.1 degrees two theta, with the absence of peaks at 6.7 and 16.8 degrees two theta ⁇ 0.1 degrees two theta wherein form K is a cyclohexane solvate.
  • form K of Ledipasvir is isolated.
  • the present disclosure comprises a crystalline form of Ledipasvir, designated form L.
  • Form L may be characterized by an X-ray powder diffraction pattern substantially as depicted in Figure 13.
  • Form L may be further characterized by an X- ray powder diffraction pattern having peaks at 3.3, 6.7, 8.7, 10.0, 12.2, 16.0, 16.8, 17.8, 18.8, 21.5, 24.9 and 26.1 degrees two theta ⁇ 0.2 degrees two theta.
  • crystalline form L may be a cyclohexane solvate. In certain embodiments, Form L may contain from about 2 % to about 7 % of cyclohexane by weight.
  • crystalline form L may be characterized by X-ray powder diffraction pattern having peaks at 3.3, 6.7, 8.7, 10.0, 16.0 and 21.5 degrees two theta ⁇ 0.1 degrees two theta wherein form L is a cyclohexane solvate.
  • form L of Ledipasvir is isolated.
  • the present disclosure comprises a crystalline form of Ledipasvir, designated form M.
  • Form M may be characterized by an X-ray powder diffraction pattern substantially as depicted in Figure 14 or Figure 15.
  • Form M may be further characterized by an X-ray powder diffraction pattern having peaks at 7.0, 11.2, 22.6 and 24.7 degrees two theta ⁇ 0.1 degrees two theta
  • crystalline form M may be an acetone/toluene solvate.
  • Form M may contain from about, 3% to about 10% of acetone by weight and from about 2% to about 10% of toluene by weight, preferably from about 3 % to about 8 % of acetone by weight and from about 2 % to about 7 % of toluene by weight.
  • crystalline form M may be characterized by an X-ray powder diffraction partem having peaks at 7.0, 11.2, 22.6 and 24.7 degrees two theta ⁇ 0.1 degrees two theta, wherein form M is an acetone/toluene solvate.
  • Form M may be further characterized by an X-ray powder diffraction partem having no peaks at 9.3, 17.8, 23.1 and 23.8 degrees two theta ⁇ 0.1 degrees two theta
  • Form M may be characterized by any one of the above embodiments or any combination thereof.
  • form M of Ledipasvir is isolated.
  • the present disclosure comprises a crystalline form of Ledipasvir, designated form N.
  • Form N may be characterized by an X-ray powder diffraction pattern substantially as depicted in Figure 16 or Figure 17.
  • Form N may be further characterized by an X-ray powder diffraction partem having peaks at 11.5, 15.2 and 19.2 degrees two theta ⁇ 0.1 degrees two theta.
  • crystalline form N may be anhydrous.
  • crystalline form N may be characterized by an X-ray powder diffraction pattern having peaks at 11.5, 15.2 and 19.2 degrees two theta ⁇ 0.1 degrees two theta, wherein form N is anhydrous.
  • Form N may be further characterized by X-ray powder diffraction pattern having peaks at 7.6 and 24.6 degrees two theta ⁇ 0.1 degrees two theta and having no peaks at 9.4, 21.3 and 21.6 degrees two theta ⁇ 0.1 degrees two theta.
  • Form N may be characterized by any one of the above embodiments or any combination thereof.
  • form N of Ledipasvir is isolated.
  • the present disclosure comprises a crystalline form of Ledipasvir, designated form O.
  • Form O may be characterized by an X-ray powder diffraction pattern substantially as depicted in Figure 18.
  • Form O may be further characterized by an X- ray powder diffraction pattern having peaks at 6.6, 9.9, 11.5, 19.6, 20.9 and 31.5 degrees two theta ⁇ 0.1 degrees two theta, X-ray powder diffraction pattern with no peaks at 7.6 and 21.3 degrees two theta ⁇ 0.1 degrees two theta; or combination thereof
  • crystalline form O may be an acetonitrile/toluene solvate.
  • Form O may contain from about 0.5 % to about 2.0 % of acetonitrile by weight and from about 2.5% to about 12% of toluene by weight, preferably from about 0.5% to about 2.0% of acetonitrile by weight and from about 3 % to about 9 % of toluene by weight, and more preferably about 2% of acetonitrile and about 9% of toluene by weight.
  • crystalline form O may be characterized by an X-ray powder diffraction pattern having peaks at 6.6, 9.9, 11.5, 19.6, 20.9 and 31.5 degrees two theta ⁇ 0.1 degrees two theta, wherein form O is an acetonitrile/toluene solvate.
  • Form O may be characterized by any one of the above embodiments or any combination thereof.
  • form O of Ledipasvir is isolated.
  • the present disclosure comprises a crystalline form of Ledipasvir, designated form P.
  • Form P may be characterized by an X-ray powder diffraction pattern substantially as depicted in Figure 29.
  • Form P may be further characterized by an X-ray powder diffraction pattern having peaks at 7.4, 9.0, 11.4, 18.8, 19.6 and 21.7 degrees two theta ⁇ 0.1 degrees two theta, X-ray powder diffraction pattern having peaks at 12.3, 20.6, 14.8, 18.2 and 24.0 degrees two theta ⁇ 0.1 degrees two theta; or combination thereof.
  • crystalline form P may be an acetonitrile/MDC
  • Form P may contain from about 2 % to about 4% of acetonitrile by weight and from about 2 % to about 4% of MDC by weight, preferably about 2% acetonitrile and about 3% of MDC by weight.
  • Form P may be characterized by an X-ray powder diffraction pattern having peaks at 7.4, 9.0, 11.4, 18.8, 19.6 and 21.7 degrees two theta ⁇ 0.1 degrees two theta wherein form P is a MDC/ acetonitrile solvate.
  • Form P may be characterized by any one of the above embodiments or any combination thereof.
  • form P of Ledipasvir is isolated.
  • the present disclosure provides a process for preparing crystalline form B comprising crystallizing Ledipasvir from a mixture of water and acetonitrile.
  • the present disclosure provides a process for preparing crystalline form B comprising a) combining ledipasvir with a solvent system comprising an organic solvent and water; b) optionally heating to a temp of about 0 °C to about 80 °C; c) cooling to about 20 °C to about 25 °C; d) optionally seeding with form B seeds; e) optionally adding water; and f) isolating Crystalline form B.
  • the organic solvent in step a is acetonitrile or acetone and the mixture in step a comprises about 20% to about 50%, more preferably about 30 % of water (by volume) in the organic solvent.
  • the heating in step b is to a temperature of about 20 °C to about 70°C and the reaction mass is stirred for 1-2 hours.
  • the process of the present disclosure is performed with stirring.
  • the crystalline form B can be isolated by any method known in the art,
  • crystalline form B of Ledipasvir can be separated by filtering the slurry or decanting the solvent from the slurry.
  • the isolating method can further comprise washing and drying the crystalline form B of Ledipasvir.
  • crystalline form B of Ledipasvir is dried at a temperature of about 50 °C to about 90 °C, more preferably at a temperature of about 70 °C to about 85 °C under reduced pressure.
  • the present disclosure provides a process for preparing crystalline form B of Ledipasvir comprising a) combining ledipasvir with a solvent system comprising 30% acetonitrile in water, b) heating to a temperature of about 20 °C to about 70 °C and stirring for 1-5 hours, c) cooling to about 20 °C to about 25 °C and optionally stirring, d) seeding with form B seeds e) adding water 3-10 vol and optionally stirring and f) isolating crystalline form B.
  • the present disclosure provides a process for preparing crystalline form G comprising crystallizing Ledipasvir from a mixture of MDC and acetone.
  • the present disclosure provides a process for preparation of form G comprising a) providing a solution of ledipasvir in MDC, b) adding acetone, c) stirring and d) separating the crystalline solid formed and optionally drying.
  • the present disclosure provides a process for preparing crystalline form G comprising recrystallizing a Ledipasvir acetone solvate from water.
  • the present disclosure provides a process for preparation of form G comprising a) providing a Ledipasvir acetone solvate in water, b) heating the reaction mass to a temperature of about 30 °C to about 60 °C, preferably to a temperature of 45 °C to about 50 °C, optionally under stirring, c) cooling to a temperature of 20 °C to about 25 °C and d) separating the crystalline solid formed and optionally drying.
  • the reaction mixture in step a and/or b is heated to about 20°C to about 40 °C, more preferably to about 35 °C.
  • the Ledipasvir acetone solvate can be Ledipasvir diacetone solvate.
  • the crystalline form G can be isolated by any method known in the art,
  • crystalline form G of Ledipasvir can be separated by filtering the slurry or decanting the solvent from the slurry.
  • the isolating method can further comprise washing and drying the crystalline form G of Ledipasvir.
  • crystalline form G of Ledipasvir is dried at a temperature of about 0°C to about 40°C under reduced pressure, more preferably at a temperature of about 30°C to about 40°C, under reduced pressure.
  • the disclosure relates to form G produced by the above described process.
  • the present disclosure provides a process for preparing crystalline form P comprising crystallizing Ledipasvir from a mixture of MDC and acetonitrile.
  • the present disclosure provides a process for preparation of form P comprising a) providing a solution of ledipasvir in MDC, b) adding acetonitrile, c) stirring and d) separating the crystalline solid formed.
  • the reaction mixture in step a and b is heated to a temperature of about 20°C to about 40°C, more preferably to a temperature of about 35°C to about 40°C.
  • the crystalline form P can be isolated by any method known in the art,
  • crystalline form P of Ledipasvir can be separated by filtering the slurry or decanting the solvent from the slurry.
  • the isolating method can further comprise washing and drying the crystalline form P of Ledipasvir.
  • crystalline form P of Ledipasvir is dried at a temperature of about 0°C to about 40°C under reduced pressure, more preferably at a temperature of about 30°C to about 40°C under reduced pressure.
  • the present disclosure provides a process for preparation of form H comprising drying of form G or form P.
  • Ledipasvir is dried at a temperature of about 40°C to about 110°C, more preferably at a temperature of about 95°C to about 100°C under reduced pressure. [00181] In another aspect the disclosure relates to form H produced by the above described process.
  • the present disclosure provides a process for preparing crystalline form M comprising crystallizing Ledipasvir from a mixture of toluene and acetone.
  • the present disclosure provides a process for preparation of form M comprising a) providing a solution comprising ledipasvir, toluene and acetone, b) stirring c) isolating crystalline form M.
  • the solution in step a comprises about 40% to about 45% of toluene (by volume) in acetone.
  • the stirring in step b is performed for about 7 to about 24 hours.
  • the reaction mixture in steps a and b is heated to a temperature of about 10°C to about 70°C , more preferably to a temperature of about 20°C to about 30°C.
  • the crystalline form M can be isolated by any method known in the art,
  • crystalline form M of Ledipasvir can be separated by filtering the slurry or decanting the solvent from the slurry.
  • the isolating method can further comprise washing and drying the crystalline form M of Ledipasvir.
  • crystalline form M of Ledipasvir is dried at a temperature of about 0°C to about 40°C under reduced pressure, more preferably at a temperature of about 30°C to about 40°C under reduced pressure.
  • the present disclosure provides a process for preparing crystalline form O comprising crystallizing Ledipasvir from a mixture of toluene and acetonitrile.
  • the present disclosure provides a process for preparation of form O comprising a) providing a solution of ledipasvir in toluene c) optionally cooling to about 25 °C to about 30 °C, d) adding acetonitrile e) optionally cooling to about 0 °C to about 5 °C, f) optionally seeding with form M seeds or form O seeds and stirring and g) isolating crystalline form O
  • the present disclosure provides a process for preparation of form O comprising a) providing a solution comprising ledipasvir, toluene and acetonitrile, optionally at elevated temperature, b) optionally adding charcoal and passing the reaction mass through diatomaceous earth (e.g. Celite ® ), c) cooling to about 25 °C to about 30 °C d) adding acetonitrile e) cooling to about 0 °C to about 10 °C, f) seeding with form M seeds or form O seeds and stirring and g) separating the crystalline solid formed.
  • diatomaceous earth e.g. Celite ®
  • step f can be performed prior to step e.
  • the solution in step a comprises about 50% to about 60% of toluene (by volume) in acetonitrile
  • the stirring in step f is for about 2 to about 30 hours
  • the drying in step g is carried for about 0.5 to about 1.0 hours at a temperature of from about 10°C to about 40°C.
  • the reaction mixture in step a is heated to a temperature of about 40°C to about 80°C, more preferably to a temperature of about 50°C to about 55°C.
  • the solution obtained in step a can be filtered, if desired, to dispose of foreign particles while maintaining the filtered solution and filtrate at almost the same temperature.
  • the crystalline form O can be isolated by any method known in the art,
  • crystalline form O of Ledipasvir can be separated by filtering the slurry or decanting the solvent from the slurry.
  • the isolating method can further comprise washing and drying the crystalline form O of Ledipasvir.
  • crystalline form O of Ledipasvir is dried at a temperature of about 0°C to about 40°C, more preferably at a temperature of about 20°C to about 30°C under reduced pressure.
  • the present disclosure provides a process for preparation of form N comprising drying of form M.
  • crystalline form M of Ledipasvir is dried at a temperature of about 50°C to about 110°C , more preferably at a temperature of about 80°C to about 105°C under reduced pressure.
  • the solid forms of the present disclosure may exhibit favourable specific surface area properties.
  • crystalline form B exhibits preferred specific surface area properties.
  • Form B exhibits a specific surface are of above 100m 2 /g, preferably of about 110m 2 /g.
  • crystalline form B exhibits a specific surface area (SSA) of from: 10-500 m 2 /g, 20-400 m 2 /g, 50-300 m 2 /g, 70-200 m 2 /g, 80-150 m 2 /g or 90-120 m 2 /g.
  • SSA specific surface area
  • crystalline form B exhibits a specific surface area (SSA) of from: 10-500 m 2 /g, 20-400 m 2 /g, 50-300 m 2 /g, 70-200 m 2 /g, 80-150 m 2 /g or 90-120 m 2 /g.
  • SSA specific surface area
  • the present disclosure relates to a solid form of Ledipasvir, preferably in crystalline form having a specific surface area (SSA) of not less than 10 m 2 /g, preferably not less than 50 m 2 /g, more preferably not less than 90 m 2 /g.
  • the solid form of Ledipasvir preferably in crystalline form has a specific surface area (SSA) of from: 10-500 m 2 /g, 20-400 m 2 /g, 50-300 m 2 /g, 70-200 m 2 /g, 80-150 m 2 /g or 90-120 m 2 /g.
  • the solid form may be any crystalline or amorphous form of
  • the crystalline form may be any one of the forms disclosed in the present application.
  • the crystalline form is form B.
  • a solid state form of Ledipasvir as described in any embodiment described herein (preferably wherein the solid state form is any one of forms B, H, N or O as defined in any embodiment described herein, or particularly one of forms H, N or O as defined in any embodiment described herein, and most preferably, forms H and N) which is non-hygroscropic.
  • non-hygroscopic it is meant that the solid state form of Ledipasvir shows a water adsorption of: ⁇ 1 wt%, ⁇ 0.8 wt%, ⁇ 0.6 wt%, ⁇ 0.5 wt%, ⁇ 0.3 wt%, ⁇ 0.1 wt%, or ⁇ 0.05 wt%, following storage at for 1 month 25°C and at 40% RH.
  • the solid state form of Ledipasvir shows a water adsorption of: ⁇ 1 wt%, ⁇ 0.8 wt%, ⁇ 0.6 wt%, ⁇ 0.5 wt%, ⁇ 0.3 wt%, ⁇ 0.1 wt%, or ⁇ 0.05 wt%, following storage at for 1 month 25°C and at 50% RH. More preferably, the solid state form of Ledipasvir shows a water adsorption of: ⁇ 1 wt%, ⁇ 0.8 wt%, ⁇ 0.6 wt%, ⁇ 0.5 wt%, ⁇ 0.3 wt% or ⁇ 0.1 wt%, following storage at for 1 month 25°C and at 60% RH.
  • the solid state form of Ledipasvir shows a water adsorption of: ⁇ 1 wt%, ⁇ 0.8 wt%, ⁇ 0.6 wt%, ⁇ 0.5 wt%, ⁇ 0.3 wt%, following storage at for 1 month 25°C and at 70% RH.
  • the solid state form of Ledipasvir shows a water adsorption of: ⁇ 1 wt%, ⁇ 0.8 wt%, ⁇ 0.6 wt% or ⁇ 0.5 wt% following storage at for 1 month 25°C and at 80% RH.
  • a pharmaceutical composition comprising a solid form of Ledipasvir as described in any embodiment, wherein the ledipasvir retains its initial solid state form.
  • the solid state form does not become sticky or viscous.
  • the term "retains its initial solid state form” means that: ⁇ 10%, ⁇ 8%, ⁇ 6%, ⁇ 5%, ⁇ 3%, ⁇ 2%, ⁇ 1%, ⁇ 0.5% or ⁇ 0.2% (more preferably ⁇ 5%, ⁇ 3%, ⁇ 2%, ⁇ 1% or ⁇ 0.5%) of the ledipasvir converts to a different solid state form, as measured by XRPD.
  • the ledipasvir may retain its initial solid state form following storage at 25°C for 1 month at: 10%-90% relative humidity (RH), 20%-90% RH, 30%-90% RH, 40%-90% RH, 50%-90% RH, 60%-90% RH, 70%-90% RH or 75%-85% RH, more preferably following storage at 25°C for 3 months at: 10%-90% relative humidity (RH), 20%-90% RH, 30%-90% RH, 40%-90% RH, 50%-90% RH, 60%-90% RH, 70%-90% RH or 75%-85% RH, and most preferably following storage at 25°C for 12 months at: 10%-90% relative humidity (RH), 20%-90% RH, 30%-90% RH, 40%-90% RH, 50%-90% RH, 60%-90% RH, 70%-90% RH or 75%-85% RH.
  • Crystalline forms M, O and P exhibit advantageous flow properties.
  • the novel crystalline form M, O, and P exhibit higher bulk density 0.274 (mg/mL),
  • the Carr's compressibility index (CI, %) and Hausner ratio (HR) were also calculated based on the equations.
  • the CI and HR were found to be relatively low for the novel crystalline form M, O and P. This is in accordance with density measurements.
  • CI is a measure of powder bridge strength and stability
  • the Hausner ratio (HR) is a measure of the interparticulate friction.
  • Flow character is rated based on compressibility index and Hausner ratio. Lower CI or lower Hausner ratios of a material indicate better flow properties than higher ones.
  • the table below shows the CI and HR values, as well as bulk densities and tap densities for forms P, O and M, according to the disclosure.
  • Crystalline forms B, G, H, M, N, O and P of the present disclosure exhibit a high level of purity, i.e. >99%.
  • the following solvent systems - acetonitrile/toluene, acetonitrile/MDC, THF/toluene, acetone/toluene/ and acetone/MDC have excellent purification power and that Ledipasvir of a purity of about 91-95% before crystallization may be purified to a level of >99% by crystallization using the above solvent systems.
  • Ledipasvir having a purity of about 91-95% before crystallization was improved to >99% when any one of forms G, M, O and P were isolated.
  • the disclosure relates to processes for purification of ledipasvir comprising crystallization from any one of the following solvent systems:
  • the crystalline forms isolated by the above processes may be forms any one of forms G, M, O or P, preferably form O or form P
  • Ledipasvir produced by the processes of the present disclosure contains about 0.1 % or less, preferably 0.08% or less, more preferably 0.05% or less of the keto impurity discussed above.
  • the content of keto- impurity ledipasvir is measured by HPLC.
  • Ledipasvir produced by the process according to any aspect or embodiment of the present disclosure may alternatively contain: ⁇ 1 wt%, ⁇ 0.8 wt%, ⁇ 0.5 wt%, ⁇ 0.25 wt%, ⁇ 0.2 wt%, ⁇ 0.1 wt% or ⁇ 0.05 wt% (preferably ⁇ 0.2 wt%, ⁇ 0.1 wt% or ⁇ 0.05 wt%, and more preferably ⁇ 0.1 wt% or ⁇ 0.05 wt%) of the keto impurity discussed above.
  • Ledipasvir produced by the processes of the present disclosure may have a total impurity content of: not more than 0.3% area percent, preferably not more than 0.2% area percent, more preferably not more than 0.1% area percent, particularly not more than 0.08% area percent, and most preferably not more than 0.05% area percent, as measured by HPLC.
  • Ledipasvir produced by the process according to any aspect or embodiment of the present disclosure may alternatively contain: ⁇ 0.5 wt%, ⁇ 0.25 wt%, ⁇ 0.2 wt%, ⁇ 0.1 wt% or ⁇ 0.05 wt% (preferably ⁇ 0.2 wt%, ⁇ 0.1 wt% or ⁇ 0.05 wt%, and more preferably ⁇ 0.1 wt% or ⁇ 0.05 wt%) of total impurities.
  • the disclosure relates to a solid form of Ledipasvir, wherein the content of the keto impurity is 0.1 % or less, preferably 0.08% or less, more preferably 0.05% or less of the keto impurity discussed above.
  • a solid form of Ledipasvir wherein the content of the keto impurity is: ⁇ 1 wt%, ⁇ 0.8 wt%, ⁇ 0.5 wt%, ⁇ 0.25 wt%, ⁇ 0.2 wt%, ⁇ 0.1 wt% or ⁇ 0.05 wt% (preferably ⁇ 0.2 wt%, ⁇ 0.1 wt% or ⁇ 0.05 wt%, and more preferably ⁇ 0.1 wt% or ⁇ 0.05 wt%).
  • the solid form may be any crystalline form, amo hous form, crystalline premix and any amorphous premix comprising ledipasvir, preferably an amorphous premix. In the case of a premix, the % of the keto impurity is calculated with respect to the amount of ledipasvir in the premix.
  • the disclosure relates to a solid form of Ledipasvir, wherein the total impurity content is not more than 0.3% area percent, preferably not more than 0.2% area percent, more preferably not more than 0.1% area percent, particularly not more than 0.08% area percent, and most preferably not more than 0.05% area percent, as measured by HPLC.
  • a solid form of Ledipasvir wherein the total impurity content is: ⁇ 0.5 wt%, ⁇ 0.25 wt%, ⁇ 0.2 wt%, ⁇ 0.1 wt% or ⁇ 0.05 wt% (preferably ⁇ 0.2 wt%, ⁇ 0.1 wt% or ⁇ 0.05 wt%, and more preferably ⁇ 0.1 wt% or ⁇ 0.05 wt%).
  • the solid form may be any crystalline form, amorphous form, crystalline premix and any amorphous premix comprising ledipasvir, preferably an amorphous premix. In the case of a premix, the % of the keto impurity is calculated with respect to the amount of ledipasvir in the premix.
  • the crystalline form may be selected from the group consisting of forms B, G, H, M, N, O and P.
  • the amorphous premix may be prepared by the processes of the present disclosure.
  • the disclosure relate to Forms G, M, O, P, B, H and N wherein the level of the keto impurity is 0.1 % or less, preferably 0.08% or less, more preferably 0.05% or less of the keto impurity discussed above.
  • the present disclosure provides Forms G, M, O, P, B, H and N of Ledipasvir wherein the level of the keto impurity is: ⁇ 1 wt%, ⁇ 0.8 wt%, ⁇ 0.5 wt%, ⁇ 0.25 wt%, ⁇ 0.2 wt%, ⁇ 0.1 wt% or ⁇ 0.05 wt% (preferably ⁇ 0.2 wt%, ⁇ 0.1 wt% or ⁇ 0.05 wt%, and more preferably ⁇ 0.1 wt% or ⁇ 0.05 wt%).
  • the disclosure relate to Forms G, M, O, P, B, H and N wherein the total impurity content is: not more than 0.3% area percent, preferably not more than 0.2% area percent, more preferably not more than 0.1% area percent, particularly not more than 0.08% area percent, and most preferably not more than 0.05% area percent, as measured by HPLC.
  • the present disclosure provides Forms G, M, O, P, B, H and N of Ledipasvir wherein the total impurity content is: ⁇ 0.5 wt%, ⁇ 0.25 wt%, ⁇ 0.2 wt%, ⁇ 0.1 wt% or ⁇ 0.05 wt% (preferably ⁇ 0.2 wt%, ⁇ 0.1 wt% or ⁇ 0.05 wt%, and more preferably ⁇ 0.1 wt% or ⁇ 0.05 wt%).
  • All of the solid state forms disclosed above can be used to prepare other solid state forms of Ledipasvir, Ledipasvir salts and their solid state forms.
  • any of the above solid state forms of ledipasvir can be used to prepare amorphous ledipasvir or ledipasvir salts.
  • forms G, M, O and P may be converted to other crystalline forms of Ledipasvir. More preferably, forms G and P may be used for preparation of form H, form M and O may be used for preparation of form N and form O, M may be used for the preparation of form B.
  • All of the solid state forms of ledipasvir disclosed above or amorphous ledipasvir can be used for preparation of Ledipasvir pre-mix.
  • the disclosure provides the use of any one of Forms G, M, O and P as well as B, H and N for the preparation of ledipasvir Premix.
  • the disclosure also provides for forms G, M, O and P as well as B, H and N for use for the preparation of ledipasvir premix
  • the Ledipasvir pre-mix can be a co-precipitate of Ledipasvir with a pharmaceutically acceptable carrier, and optionally other pharmaceutically acceptable excipients.
  • a pharmaceutically acceptable carrier is copovidone.
  • the Ledipasvir premix can be a crystalline premix or an amorphous premix.
  • the pre-mix of Ledipasvir and the carrier preferably
  • copovidone contains a weight ratio of carrier: Ledipasvir of: about 7:3 to about 3:7, about 6:4 to about 4:6, about 45:55 to about 55:45, about 50:50.
  • the pre-mix comprises the carrier, preferably copovidone, in an amount of about 70 to about 30 wt%, about 40 to about 60 wt%, about 50 wt%.
  • the pre-mix comprises Ledipasvir in an amount of about 70 to about 30 wt%, about 60 to about 40 wt%, about 50 wt%.
  • the present disclosure relates to processes for preparation of a premix of Ledipasvir comprising combining any one of the above solid state forms of Ledipasvir with a pharmaceutically acceptable carrier, preferably copovidone, and optionally other pharmaceutically acceptable excipients.
  • a pharmaceutically acceptable carrier preferably copovidone, and optionally other pharmaceutically acceptable excipients.
  • Ledipasvir amorphous pre-mix can be prepared by mixing Ledipasvir with at least one carrier, preferably copovidone, and optionally other pharmaceutically acceptable excipients or mixture of excipients, providing a mixture that is then combined with an alcohol such as ethanol, isopropanol, or the like, to yield a second mixture.
  • an alcohol such as ethanol, isopropanol, or the like
  • both ledipasvir and the carrier are dissolved in the second mixture.
  • the solvent is then removed from the second mixture by evaporation techniques such as spray drying, EKATO or rotavapor.
  • the resulting mixture may be in the form of a powder, which may be subjected to a particle size reduction step (e.g., by milling).
  • Ledipasvir amorphous pre-mix can be prepared by mixing any one of the above solid state forms of Ledipasvir with copovidone and optionally other pharmaceutically acceptable excipients, providing a mixture that is then combined with ethanol to yield a second mixture.
  • the solvent is then removed from the second mixture by evaporation techniques such as spray drying, an agitated dryer (e.g. EKATO).
  • EKATO agitated dryer
  • the resulting mixture may be in the form of a powder, which may be subjected to a particle size reduction step (e.g., by milling).
  • Ledipasvir crystalline pre-mix can be prepared by dissolving the carrier, such as copovidone, in a solvent such as water, adding ledipasvir and removing the solvent by methods such as lyophilization or vacuum distillation.
  • the ledipasvir is not dissolved in the solution of the carrier and the solvent.
  • the resulting mixture may be in the form of a powder, which may be subjected to a particle size reduction step (e.g., by milling).
  • Ledipasvir crystalline pre-mix can be prepared by adding the carrier, such as copovidone, to a solvent such as water, heating the reaction mass to a temp in the range of about 30 deg. C to about 65 deg. C to afford a clear solution, adding ledipasvir with stirring to provide a mixture that is then lyophilized.
  • the resulting mixture may be in the form of a powder, which may be subjected to a particle size reduction step (e.g., by milling).
  • the present disclosure relates to processes for preparation of a premix of Ledipasvir and other active pharmaceutical ingredients, preferably sofosbuvir and/or velpatasvir and/or other API 's which can be used in combination with Ledipasvir, comprising combining any one of the above solid state forms or amorphous form of Ledipasvir with any form of Sofosbuvir and/or any form of Velpatasvir with a
  • pharmaceutically acceptable carrier preferably preferably copovidone, and optionally other pharmaceutically acceptable excipients.
  • the present disclosure also provides solid state forms of Ledipasvir for use in the preparation of pharmaceutical compositions of Ledipasvir optionally with other API 's which can be used in combination with Ledipasvir,. In some embodiments, the present disclosure also encompasses the use of the Ledipasvir solid state forms of the present disclosure for the preparation of pharmaceutical compositions of Ledipasvir.
  • the present disclosure further comprises processes for preparing the above mentioned pharmaceutical compositions. The processes comprise combining the Ledipasvir solid state forms with at least one pharmaceutically acceptable excipient.
  • the solid state forms and the pharmaceutical compositions of Ledipasvir of the present disclosure can be used as medicaments, particularly for the treatment of Hepatitis C.
  • the present disclosure also provides methods of treating Hepatitis C, comprising administering a therapeutically effective amount of a Ledipasvir solid state form of the present disclosure, or at least one of the above pharmaceutical compositions, to a subject suffering from Hepatitis C, or otherwise in need of the treatment.
  • the present disclosure also provides amorphous Ledipasvir or Ledipasvir premix prepared by the processes of the disclosure for use in the preparation of pharmaceutical compositions of Ledipasvir.
  • the present disclosure also encompasses the use of amorphous Ledipasvir or Ledipasvir premix prepared by the processes of the disclosure for the preparation of pharmaceutical compositions of Ledipasvir.
  • the present disclosure further comprises processes for preparing the above mentioned pharmaceutical compositions.
  • the processes comprise combining amorphous Ledipasvir or Ledipasvir premix prepared by the processes of the disclosure with at least one pharmaceutically acceptable excipient.
  • Amorphous Ledipasvir or Ledipasvir premix prepared by the processes of the disclosure and the pharmaceutical compositions of Ledipasvir of the present disclosure can be used as medicaments, particularly for the treatment of Hepatitis C.
  • the present disclosure also provides methods of treating Hepatitis C, comprising administering a therapeutically effective amount of amorphous Ledipasvir or Ledipasvir premix prepared by the processes of the disclosure, or at least one of the above pharmaceutical compositions, to a subject suffering from Hepatitis C, or otherwise in need of the treatment.
  • the disclosure provides a process for the preparation of Ledipasvir that comprising:
  • the amine protecting group of the compounds of formula 8 and 9 may be Fmoc, Cbz, benzyl, trityl, Boc, trifluoroacetyl derivative, phthalic anhydride derivative, most preferably, the amine protecting group is Boc.
  • X is chloro or bromo.
  • Compound 10 may be in free base form, or may be acid salt (e.g. a mono, di or triacid salt of a monovalent acid such as HCl). Preferably compound 10 is a tri-HCl salt.
  • Step a) is typically carried out in the presence of a suitable solvent, a suitable coupling agent and a suitable base.
  • Suitable solvents may include, for example, pentane, cyclohexane, methyl cyclohexane, toluene, diisopropyl ether, t-butyl methyl ether, ethyl acetate, 2- methoxy ethyl ether (diglyme), tetrahydrofuran (THF), methylene chloride, 2-butanone, acetone, acetonitrile, sulfolane, dimethyl sulfoxide (DMSO), 2-methyl tetrahydrofuran, dimethyl formamide (DMF), xylene, water or mixture thereof.
  • the solvent is DMF, DMSO, 2-methyltetrahydrofuran, THF, toluene, acetonitrile, water or combination thereof.
  • the solvent is a combination of DMF, 2- methyltetrahydrofuran and water.
  • Suitable coupling agents may include, for example metals like Pd, Pt, Rh, and ligand like PPh 3 , CI2, NO2, CN, dppa (diphenylphosphoryl azide), dba
  • the coupling agent is a metal complex, preferably Pd((PPh) 3 ) 4 , PdCl 2 (PPh) 3 , PdCl 2, [(Pt-Bu) 2 Ph] 2 , Pd(OAc) 2 , Pd(OAc) 2 (PPh) 3 , Pd(dba) 3 , Pd(dppf)Cl 2 , [ Pd(dppb)Cl 2 ], Pd(dpa) 2 ,(dppf), Pd(dba) 3 , Pd(Pt- Bu) 3 .
  • Pd((PPh) 3 ) 4 PdCl 2 (PPh) 3 , PdCl 2, [(Pt-Bu) 2 Ph] 2 , Pd(OAc) 2 , Pd(OAc) 2 (PPh) 3 , Pd(dba) 3 , Pd(dppf)Cl 2 , [ Pd(dppb)Cl 2 ], Pd(d
  • the coupling agent is Pd(OAc) 2 ,PPh 3 , Pd(OAc) 2 (PPh) 3 , Pd((PPh) 3 ) 4 , PdCl 2 (PPh) 3 , PdCl 2 [(Pt-Bu) 2 Ph] 2 .
  • Suitable bases may include organic and inorganic bases, for example, Na2C03, K2C03, NaHC03, DIPEA (N,N-Diisopropylethylamine), TEA (triethylamine) and NMM (N-Methylmorpholine).
  • the base may be Na 2 C0 3 , or K 2 C0 3 .
  • Most preferably the base may be Na 2 C0 3 .
  • Step a may be carried out at a temperature ranging from about 50°C to about 100°C, preferably step a is carried out at a temperature of from about 65°C to about 80°C.
  • Step b) involves removal of the amine protecting group and is typically carried
  • Suitable solvents may include, for example, Methanol, Ethanol, Isopropanol, acetone, Acetonitrile, THF, 2-methyl
  • the solvent is Acetonitrile, acetone, water, Me-THF, THF, methanol, ethanol, isopropanol or combination thereof.
  • the solvent is Acetone, acetonitrile or Me-THF.
  • Suitable deprotecting reagents for step (b) include, but are not limited to, PTSA (p-toluene sulfonic acid), H 3 PO4, Hydrochloric acid, Trifluoroacetic acid, Tetra-n- butylammonium bromide, sulfuric acid, HBr, acetic acid, Methane sulfonic acid, inorganic and organic acid and combination thereof.
  • PTSA p-toluene sulfonic acid
  • H 3 PO4 Hydrochloric acid
  • Trifluoroacetic acid Trifluoroacetic acid
  • Tetra-n-butylammonium bromide sulfuric acid
  • HBr acetic acid
  • Methane sulfonic acid inorganic and organic acid and combination thereof.
  • the deprotecting reagent is
  • hydrochloric acid HBr in acetic acid. More preferably, the deprotection is performed in the presence of Hydrochloric acid.
  • Step c) is typically carried out in the presence of a suitable solvent and a suitable coupling agent.
  • Suitable solvent may include, for example, DMF, DMSO, 2- methyltetrahydrofuran, THF, Toluene and acetonitrile, acetone, MDC, water or combination thereof.
  • the solvent may be DMF, DME (dimethoxy ethane), DMSO, acetonitrile, acetone, toluene, MDC, DMAC ((dimethylacetamide?),Me-THF, THF or combination thereof. More preferably, the solvent may be DMF, Toluene or Me-THF.
  • a suitable coupling agent for step (c) may be agents that can activate the acid to RCO-L, where in L is better leaving group such as halides, mix anhydrides or other groups described for the activation of acid in the literature.
  • Suitable coupling agents may include, for example HATU [l-[Bis(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5- b]pyridinium 3-oxid hexafluorophosphate], EDC HC1 (l-Ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride), HOBt (1 -Hydroxy benzotriazole
  • the coupling agent is CDI, HATU and EDC/HOBt. Most preferably, the coupling agent is HOBt and EDC HC1.
  • the process further comprises the generation of compound of formula 7 by a process that comprises;
  • PG1 is an amine-protecting group, preferably wherein the amine protecting group is Fmoc, Cbz, benzyl, trityl, Boc, trifluoroacetyl derivative, phthalic anhydride derivative, and most preferably, wherein the amine protecting group is Boc, and X is halo, preferably bromo.
  • Compound 6 may be in free base form, or may be acid salt (e.g. a mono, di or triacid salt of a monovalent acid such as HC1). Preferably compound 6 is a di HC1 salt.
  • acid salt e.g. a mono, di or triacid salt of a monovalent acid such as HC1.
  • compound 6 is a di HC1 salt.
  • Step i) involves removal of the amine protecting group PG1 and is typically carried out in the presence of a suitable solvent.
  • suitable solvents may include, for example Methanol, Ethanol, n-propanol, Isopropanol, acetone, Acetonitrile, THF, 2-methyl tetrahydrofuran, Ethylacetate, toluene, xylene and combination thereof.
  • the solvent is Acetonitrile, Isopropanol or acetone.
  • the solvent is acetone.
  • Suitable deprotecting reagents include, but are not limited to, PTSA,
  • H 3 P0 4 Hydrochloric acid, Trifluoroacetic acid, Tetra-n-butylammonium bromide, Sulfuric acid, MSA (methane sulfonic acid), organic and inorganic acid and mixture of these.
  • the deprotecting reagent is selected from PTSA, and hydrochloric acid. Most preferably, the deprotection is performed in the presence of Hydrochloric acid.
  • Step ii) is typically carried out in the presence of a suitable solvent and suitable coupling agent.
  • suitable solvents may include, for example Pentane, cyclohexane, methyl cyclohexane, Toluene, Diisopropyl ether, t-Butyl methyl ether, ethyl acetate, 2- methoxy ethyl ether(diglyme), Tetrahydrofuran, Methylene chloride, 2-Butanone, acetone acetonitrile, sulfolane, dimethyl sulfoxide, 2-methyl tetrahydrofuran, dimethyl formamide, NMP, Dimethyl acetamide (DMAc) and xylene or mixture of Xylenes.
  • DMAc Dimethyl acetamide
  • the solvent is DMF, 2-methyl tetrahydrofuran, THF, DMSO, Toluene, DMAc, acetonitrile, acetone, and may be a single solvent or combination thereof. Most preferably, the solvent is DMF and acetonitrile.
  • Suitable coupling agents for step ii) are the same as the coupling agents for step c) above.
  • step ii) is carried out at a temperature ranging from about -30°C to about 60°C.
  • step ii) is performed at a temperature ranging from about 0°C to about 10°C.
  • process further comprises the generation of compound of formula 5 by a process that comprises:
  • step A may be performed in the presence of a suitable organic base.
  • suitable organic bases may include, for example, DIPEA, DIP A, TEA, NMM, Morpholine, Pyridine and Inorganic bases like NaHC0 3 , K 2 C0 3 and Na 2 C0 3 .
  • the organic base is DIPEA.
  • step A is carried out at a temperature ranging from about 35°C to about 100°C.
  • step B compound 4 may be reacted with a source of ammonia.
  • Suitable sources of ammonia may include, for example, ammonium acetate or ammonium hydroxide.
  • the source of ammonia is ammonium acetate.
  • step B is carried out at a temperature ranging from about 60°C to about 120°C.
  • steps A and B of the above process are performed in a single solvent.
  • Suitable solvents may include, for example, cyclohexane, methyl cyclohexane, Toluene, Diisopropyl ether, t-Butyl methyl ether, ethyl acetate, 2- methoxy ethyl ether(diglyme), isopropyl acetate Tetrahydrofuran, acetone, acetonitrile Methylene chloride, 2-Butanone, acetone acetonitrile, sulfolane, dimethyl sulfoxide, 2-methyl tetrahydrofuran, dimethyl formamide, NMP, Dimethyl acetamide and xylene, mixture of Xylenes.
  • the solvent is selected from Toluene, acetonitrile, acetone, ethylacetate, xylene, ethanol, IPA or Tetrahydrofuran.
  • the solvent is selected from Toluene, Acetonitrile, acetone and ethanol.
  • the disclosure provides a process for the preparation of Ledipasvir that comprises the following steps:
  • the coupling agent in step a) is selected from a group consisting of a metal complex, preferably Pd((PPh) 3 ) 4 , PdCl 2 (PPh) 3 , PdCl3 ⁇ 4 [(Pt-Bu) 2 Ph] 2 , Pd(OAc) 2 , Pd(OAc) 2 (PPh) 3 , Pd(dba) 3 , Pd(dppf)Cl 2 , [ Pd(dppb)Cl 2 ],
  • a metal complex preferably Pd((PPh) 3 ) 4 , PdCl 2 (PPh) 3 , PdCl3 ⁇ 4 [(Pt-Bu) 2 Ph] 2 , Pd(OAc) 2 , Pd(OAc) 2 (PPh) 3 , Pd(dba) 3 , Pd(dppf)Cl 2 , [ Pd(dppb)Cl 2 ],
  • the coupling agent is
  • the coupling agent in step c) is an agent that can activate the acid to RCO-L, where in L is better leaving group such as halides, mix anhydrides or other groups described for the activation of acid in the literature, more preferably, the coupling agent is HOBt and EDC HC1.
  • the process further comprises the generation of compound of formula 7a by a process that comprises:
  • the coupling agent in step c) is an agent that can activate the acid to RCO-L, where in L is better leaving group such as halides, mix anhydrides or other groups described for the activation of acid in the literature.
  • the coupling agent is HOBt and EDC HC1 and step ii is carried out at a temperature ranging from about -30°C to about 60°C.
  • step ii) is performed at a temperature ranging from about 0°C to about 10°C.
  • process further comprises the generation of compound of formula 5a by a process that comprises:
  • the disclosure provides a process for the preparation of Ledipasvir that comprises the following steps:
  • step ii) wherein the compound of formula 6a is isolated and step ii) is carried out at a temperature ranging from about -30°C to about 60°C.
  • step ii) is performed at a temperature ranging from about 0°C to about 10°C.
  • step ii) Reacting a compound of formula 7a, with a compound of formula 8a, in the presence of Pd(OAc)2/PPh 3 /Na 2 C0 3 o provide a compound of formula 9a;
  • Step size 0.05 °
  • Sample holder PMMA specimen holder ring. Specific Surface Area analysis
  • SSA is usually measured by nitrogen absorption analysis.
  • nitrogen is absorbed on the surface of the substance.
  • the amount of the absorbed nitrogen is related to the surface area via a formula known as the B.E.T. formula.
  • An instrument by Micromeritics TriStar II Plus and Other commercial instrument manufactured by quantachrome (for example model monosorb) are used for this study.
  • the analysis may be performed in a single test (single point measurement) or in a series of tests in various nitrogen pressures (multipoint measurement). Before the Surface area analysis all the samples were degassed at 40 deg C for 3 hours.
  • the moisture sorption desorption isotherms were acquired using a DVS Advantage moisture sorption analyzer (Surface measurement system, Ltd). The samples were weighed into Glass sample holders. The measurement cycles for the novel crystalline form according to the present disclosure were started at 0 % RH, increased in % steps to 10 % RH, further increased in 10 % steps to 80 % RH and subsequently increased to 95 % RH, decreased again to 90 % RH, decreased in 10 % steps to 10 % RH, further decreased in 10 % steps to 0 % RH,
  • Buffer 0.3% v/v Solution of Perchloric acid and 0.15%v/v solution of ortho phosphoric acid in water adjust pH 2.0 with 5% Sodium hydroxide solution.
  • Reaction mass was cool to 0 - 5° C and added 100 gm on dry basis of methyl ((R)- l-((S)-6-(4-(7-(2-((lR,3S,4S)-2-azabicyclo[2.2.1]heptan-3-yl)-lH-benzo[d]imidazol-6-yl)- 9,9-difluoro-9H-fluoren-2-yl)-lH-imidazol-2-yl)-5-azaspiro[2.4]heptan-5-yl)-3-methyl-l- oxobutan-2-yl)carbamate hydrochloride salt then added 72.10 gm N- methyl morpholine at 0 - 5°C slowly over the period of 15 - 30 min and reaction mass was stirred for 3 h.
  • Reaction temperature was raised to 10-20 °C and added 10 gm of EDC.HC1 at the same temperature and stirred for 6 hrs.
  • Total reaction volume was 860 ml.
  • Out of 860 ml of the reaction mass 43 mL was taken out for other experiment.
  • 500 mL of water was added and stirred for 2 h.
  • Precipitated material was separated through filtration and washed with 500 ml of water to give Part A .
  • 43 ml of 860 ml of the reaction mass was added drop-wise to a 2% acetic acid solution 80 mL and precipitated material was separated through filtration and washed with 50 ml of water to give Part-B.
  • Ledipasvir diacetonate may be prepared according to example 1 of WO 2013/184698.
  • Ledipasvir (Acetone solvate form II, 4.20 g, 0.0044 moles) was dissolved in DMF (50.4 ml) at 20-30°C, water (150 ml) was added, and the mass was stirred 3 h at 20- 30°C. The product was isolated by filtration, washed with water, and then dried ⁇ 40°C under vacuum for 15-20 h.
  • Ledipasvir acetone solvate (form II, 1.0 g) was dried at 115°C for 4-6 h without vacuum and the sample was analyzed by XRD. The obtained product was analyzed by XRPD and the XRPD pattern is presented in Figure 7.
  • Amorphous Ledipasvir 250 mg was suspended in cyclohexane (5 ml) at 25°C, heated to 60-65°C, and the suspension was heated for 2h and 30 min. MDC (1.0 ml) was then added drop wise to obtain a clear solution. The reaction mixture was allowed to cool at 20-25°C gradually and was then stirred for 6 h at 20-22°C. The formed solid material was separated by filtration and dried under vacuum at 20-25°C for 30 min. The product was analyzed by XRPD and the XRPD partem is presented in Figure 1.
  • Amorphous Ledipasvir (2 g) was suspended in cyclohexane (40 ml) at 20- 25°C, heated to 60-65°C and MDC (20 ml) was added slowly drop wise to obtain a clear solution. Stirring was continued for 2 h. The solution was allowed to cool to 20-25°C gradually and the mixture was stirred for 6 h at 20-25°C. The solid material was separated by filtration and dried under vacuum at 20-25°C for 30 min to give 2.0 gm Ledipasvir Form-A (as confirmed by XRPD).
  • Example 2 Preparation of Crystalline form B of Ledipasvir
  • Amorphous Ledipasvir 250 mg was suspended in 30% water in acetonitrile (1.5 ml) and heated to 60-65°C. The solution was stirred for 1 h. The reaction mixture was allowed to cool to 25°C gradually and stirred for 16 h at 20-25°C. The formed solid material was separated by filtration at 20-25°C and dried under vacuum at 20-22°C for 30 min. The product was analyzed by XRPD and the XRPD pattern is presented in Figure 2.
  • Amorphous Ledipasvir 500 mg was suspended in 30% water in acetonitrile (3.0 ml) at 20-25°C and heated to 60-65°C to obtain a clear solution. The solution was stirred for 1 h. The reaction mixture was allowed to cool to 25°C gradually and stirred for 16 h at 20-25°C. The solid material was separated by filtration at 20-25°C and dried under vacuum at 20-25°C for 30 min. Form B was obtained as analyzed by XRD.
  • morphous Ledipasvir 500 mg was suspended in 30% water in acetonitrile (5.0 ml) at 20-25°C and heated to 60-65°C to obtain a clear solution. The solution was stirred for 1 h. The reaction mixture was allowed to cool to 25°C gradually and stirred for 22 h at 20-25°C. The solid material was separated by filtration at 20-25°C and dried under vacuum at 20-25°C for 30 min. Form B was obtained as analyzed by XRD.
  • Amorphous Ledipasvir 250 mg was suspended into 5% water MIBK solution (10 v) at 25°C and the suspension was heated to 60-65°C to obtain a clear solution. The solution was then stirred for 4 h at the same temperature and gradually cooled to 20- 25°C. The reaction mixture was stirred for 24 h at 20-25°C. Cyclohexane (4v) was added slowly and the reaction mixture further cooled to 5-10°C for 30 min. The formed solid material was separated using filtration and dried under vacuum for 30 min at 20-25°C. The product was analyzed by XRPD and the XRPD partem is presented in Figure 3.
  • Amorphous Ledipasvir (0.5 gm) was suspended into cyclohexane (5 vol.) at 20-30°C and heated to 50-60°C, then acetone (5.0 vol.) was added at the same temperature and maintained for 30 min. The reaction flask was allowed to come to 20- 30°C and stirred for 18 hrs. The crystallized product was isolated through filtration, washed with 2 vol. of cyclohexane and dried under vacuum at 20-30°C for 30 min. to give 0.35 gm Ledipasvir. The product was analyzed by XRPD and the XRPD pattern is presented in Figure 10.
  • Amorphous Ledipasvir (0.3 gm) was dissolved into the THF (1.0 ml) at 20- 25°C, methylethylketone (1.0 ml) was added and stirred for 24 hrs at 20-25°C. To the solution, acetonitrile (1.5 ml) was added and stirred for 12 hrs. The crystallized product was isolated through filtration, and dried under vacuum at 20-30°C for 30 min. to give 0.15 gm of Ledipasvir form C (as confirmed by XRPD).
  • Amorphous Ledipasvir (3 g) was mixed with a solution of THF/acetonitrile in a 1 : 1 ratio at 25°C and the mixture stirred for 18 h. The precipitate was separated through filtration and the filtered material was washed with THF/acetonitrile (2 ml, 1: 1 ratio) solution at 25°C and dried under vacuum for 30 min to give 2.25 g of Ledipasvir form D (as confirmed by XRPD).
  • Amorphous Ledipasvir 250 mg was added to a 10 ml round bottom flask followed by addition of 30% water acetone solution (2.5 ml) at 60°C, slowly drop wise. The reaction mixture was allowed to cool at 20-25 °C gradually and stirred for 24 h at 20-25°C. The solid material was separated using filtration and the filter cake was washed with 33% water acetone solution and dried under vacuum for 30 min at 20-25°C. The product was analyzed by XRPD and the XRPD pattem is presented in Figure 5.
  • Form G of Ledipasvir acetonate (0.1 g) was added to a TGA (TA instrument Q500) platinum pan and heated to 150°C under nitrogen atmosphere at a rate of 10°C/min. The sample was kept at 150°C for 10 min, then cooled to 40°C. The solid material was removed at 20-25°C. The product was analyzed by XRPD and the XRPD partem is presented in Figure 9.
  • reaction mass was heated to 60-70°C for 30 min.
  • 0.5 gm charcoal was added and stirring was continued for 15 min.
  • the reaction mass was passed through celite pad and washed with 10 ml of Toluene. Filtrate was concentrated to attain 25 ml residual volume.
  • Reaction mass was cooled to 25°C and then 20 ml of acetonitrile was added at same temperature and cooled to 0-5°C and 150 mg of Form-M seed was added. Then stirring was maintained for next 9.0 hrs at 5-10°C.
  • Crystallized product was separated through filtration at 5-10°C, washed with 5.0 mL acetonitrile and toluene (4:5 ratio) solution. Wet material was dried at 40°C under vacuum for 30 min. to give 3.91 gm Form-O, as confirmed by XRD, having Purity >99.0 %
  • reaction mass was warmed to 20-25 °C and stirred for 2 h 30 min. Again added 2.5 gm EDC.HCl and stirred for 14 h at 20-25 °C.
  • OVI Organic Volatile Impurity
  • Ledipasvir 0.5 gm form P was kept in vacuum oven and heated at 75°C under -0.1 M pa for 2.5 hrs. The oven temperature was cooled to 40°C and then the vacuum was released. The sample was taken out from the oven. The obtained product was analyzed by XRPD and was identified as form H.
  • Copovidone 5 gm was charged 200 mL of water at 25°C. Reaction mass was heated to 60-65°C to get clear solution and added 5gm of Ledipasvir form-II with gentle stirring and frozen using liquid Nitrogen and then lyophilized in a lyopholizer resulting in Ledipasvir premix crystalline form-II. The obtained product was analyzed by XRPD and the XRPD pattern is presented in Figure 30
  • Copovidone 5 gm was charged 200 mL of water at 25°C. Reaction mass was heated to 35-40°C to get clear solution and added 5gm of Ledipasvir form-H with gentle stirring and Freeze it by using liquid Nitrogen. Lyophilize it in lyophilizer giving Ledipasvir premix crystalline From-H. The obtained product was analyzed by XRPD and the XRPD pattern is presented in Figure 31
  • Copovidone 5 gm was charged 150 mL of water at 25°C. Reaction mass was heated to 35-40°C to get clear solution and added 5.0gm of Ledipasvir form-N with gentle stirring and Freeze it by using liquid Nitrogen. Lyophilize it in lyophilizer giving Ledipasvir premix crystalline form-N. The obtained product was analyzed by XRPD and the XRPD pattern is presented in Figure 32.
  • Copovidone 5 gm was charged 100 mL of water at 25°C. Reaction mass was heated to 60°C to get clear solution and added 5gm of Ledipasvir form-0 with gentle stirring and Freeze it by using liquid Nitrogen and then lyophilized in lyophilizer to afford Ledipasvir premix crystalline form-O. The obtained product was analyzed by XRPD and the XRPD pattern is presented in Figure 33.
  • Example 22 Preparation of amorphous Ledipasvir
  • reaction mass was cooled to 35-40°C, organic layer was separated out and washed with 400 ml of water and with 400ml 10% brine solution. The organic layer was separated out and 10 gm activated Carbon were charged and stirred for 30 min at 35- 45°C.
  • the reaction mass was heated to reflux, the reflux was continued till reaction complies.
  • the reaction mass was cooled to 30-45°C, the organic layer was separated out washed with 600 mL water, and twice with 600 mL 10% brine solution.
  • the organic layer was separated out and 15 gm of activated Carbon was charged and the reaction mass was stirred for 30 min at 35-45°C, filtered through hyflo bed and washed the bed with 300 mL of 2 Methyl THF, total weight of Organic layer was 1269 gm.
  • the obtained organic layer was divided into 3 equal part i.e 423 gm each Compound 9a.
  • Compound 10a may be converted to ledipasvir according to the procedure described above, or by the following procedure:
  • reaction mixture was stirred for another 15 hrs at 10-20°C, reaction monitored by HPLC. After completion of reaction, 1000 ml Ethyl acetate was charged followed by 800 ml water. The reaction mass was stirred for 30-40 min at 10-25°C, the organic layer was separated out and washed with 500 ml 2% acetic acid solution. The separated organic layer was again washed 500 ml of water followed by 10% brine solution (2*500 ml). The organic layer was charged into another reactor and 10 gm of activated carbon was added and the reactor was heated to reflux. Reflux was continued for 30 min the reaction mass was filtered through hyflo bed, and washed with 200 ml ethyl acetate.
  • ledipasvir Premix may be a crystalline premix of Ledipasvir or an amorphous premix.
  • a pharmaceutical composition comprising a solid form of Ledipasvir according to any one of the following claims 1-25, 31 , 38, 43, 46, 52, 60 and 63, a crystalline premix of Ledipasvir according to claim 64 or an amorphous premix according to
  • Embodiment (F), or combination thereof are examples of Embodiment (F), or combination thereof.
  • (L) A process for preparation of a pharmaceutical composition according to any of Embodiments (I)-(K), comprising combining the solid form of ledipasvir according to any one of the following claims 1-25, 31 , 38, 43, 46, 52, 60 and 63, a crystalline premix of Ledipasvir according to the following claim 64, or an amorphous premix according to Embodiment (F) with at least one pharmaceutically acceptable excipient.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des formes solides de lédipasvir, des compositions pharmaceutiques de celui-ci et des procédés pour la préparation de lédipasvir.
PCT/US2016/021905 2015-03-12 2016-03-11 Formes solides de lédipasvir et procédés pour la préparation de lédipasvir Ceased WO2016145269A1 (fr)

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
IN673DE2015 2015-03-12
IN673/DEL/2015 2015-03-12
IN962DE2015 2015-04-06
IN962/DEL/2015 2015-04-06
IN1058DE2015 2015-04-16
IN1058/DEL/2015 2015-04-16
IN1625/DEL/2015 2015-06-04
IN1625DE2015 2015-06-04
IN2011/DEL/2015 2015-07-03
IN2011DE2015 2015-07-03
IN2171/DEL/2015 2015-07-17
IN2171DE2015 2015-07-17
IN2356/DEL/2015 2015-07-31
IN2356DE2015 2015-07-31
IN3612/DEL/2015 2015-11-05
IN3612DE2015 2015-11-05
IN4327DE2015 2015-12-30
IN4327/DEL/2015 2015-12-30
IN201611004860 2016-02-11
IN201611004860 2016-02-11

Publications (1)

Publication Number Publication Date
WO2016145269A1 true WO2016145269A1 (fr) 2016-09-15

Family

ID=55588630

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/021905 Ceased WO2016145269A1 (fr) 2015-03-12 2016-03-11 Formes solides de lédipasvir et procédés pour la préparation de lédipasvir

Country Status (1)

Country Link
WO (1) WO2016145269A1 (fr)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132601A1 (fr) 2009-05-13 2010-11-18 Gilead Sciences, Inc. Composés antiviraux
US20110306541A1 (en) * 2010-06-10 2011-12-15 Gilead Sciences, Inc. Methods for treating hcv
WO2013101550A1 (fr) 2011-12-29 2013-07-04 Abbvie Inc. Compositions solides
WO2013184702A1 (fr) 2012-06-05 2013-12-12 Gilead Sciences, Inc. Synthèse de composé antiviral
WO2013184698A1 (fr) 2012-06-05 2013-12-12 Gilead Sciences, Inc. Formes solides d'un composé antiviral
WO2014120982A1 (fr) 2013-01-31 2014-08-07 Gilead Pharmasset Llc Formulation de dispersion solide d'un composé antiviral
WO2014120981A1 (fr) 2013-01-31 2014-08-07 Gilead Pharmasset Llc Formulation de combinaison de deux composés antiviraux
CN104961733A (zh) 2015-07-06 2015-10-07 上海众强药业有限公司 雷迪帕韦新晶型及其制备方法
CN105237517A (zh) 2015-10-30 2016-01-13 南京正大天晴制药有限公司 结晶的雷迪帕韦化合物及其制备方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132601A1 (fr) 2009-05-13 2010-11-18 Gilead Sciences, Inc. Composés antiviraux
US8088368B2 (en) 2009-05-13 2012-01-03 Gilead Sciences, Inc. Antiviral compounds
US20110306541A1 (en) * 2010-06-10 2011-12-15 Gilead Sciences, Inc. Methods for treating hcv
WO2013101550A1 (fr) 2011-12-29 2013-07-04 Abbvie Inc. Compositions solides
WO2013184702A1 (fr) 2012-06-05 2013-12-12 Gilead Sciences, Inc. Synthèse de composé antiviral
WO2013184698A1 (fr) 2012-06-05 2013-12-12 Gilead Sciences, Inc. Formes solides d'un composé antiviral
WO2014120982A1 (fr) 2013-01-31 2014-08-07 Gilead Pharmasset Llc Formulation de dispersion solide d'un composé antiviral
WO2014120981A1 (fr) 2013-01-31 2014-08-07 Gilead Pharmasset Llc Formulation de combinaison de deux composés antiviraux
CN104961733A (zh) 2015-07-06 2015-10-07 上海众强药业有限公司 雷迪帕韦新晶型及其制备方法
CN105237517A (zh) 2015-10-30 2016-01-13 南京正大天晴制药有限公司 结晶的雷迪帕韦化合物及其制备方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAIRA: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP008166276, ISSN: 0340-1022 *
GREEN ET AL.: "Protective Groups in Organic Chemistry", 1991, WILEY
HARRISON ET AL.: "Compendium of Synthetic Organic Methods", vol. 1-8, 1971, JOHN WILEY AND SONS
J. MED CHEM., vol. 57, no. 5, 2014, pages 2033 - 2046

Similar Documents

Publication Publication Date Title
JP5264830B2 (ja) アミノクロトニル化合物の調製方法
US11149017B2 (en) Solid state forms of apalutamide
WO2010139979A2 (fr) Procédés d'élaboration de formes cristallines
EA022756B1 (ru) Кристаллические формы элтромбопага и их применение
KR102776189B1 (ko) 발베나진의 고상 형태
EP3426655A1 (fr) Formes solides du vénétoclax et procédés de préparation du vénétoclax
EP2870154A1 (fr) Forme solide du sel de choline de vemurafénib
JP2012515210A (ja) ベンダムスチン遊離塩基の新規の形態
WO2019008520A1 (fr) Procédé de préparation d'alectinib ou d'un sel pharmaceutiquement acceptable de celui-ci
CN101939314B (zh) 3-吡咯取代的2-吲哚酮的多晶型物
US12116374B2 (en) Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
WO2020051014A1 (fr) Procédés pour la préparation de ténapanor et d'intermédiaires de ceux-ci
TWI724651B (zh) 貝前列素-314d單水合物晶體及其製備方法
CN111484488A (zh) 一种b-raf激酶二聚体抑制剂的稳定结晶形式a
WO2016145269A1 (fr) Formes solides de lédipasvir et procédés pour la préparation de lédipasvir
WO2020053795A2 (fr) Procédé de préparation d'acalabrutinib et de ses intermédiaires
KR20210135530A (ko) Flna-결합 화합물 및 이의 하이드로클로라이드 염의 고체 다형체
WO2008051440A1 (fr) Modifications cristallines
EP4384525A1 (fr) Formes à l'état solide de rélugolix
WO2019048974A1 (fr) Procédé de préparation de nintédanib
TWI918288B (zh) 1-((3S,4R)-3-((2-((1-乙基-1H-吡唑-4-基)胺基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)-4-氟哌啶-1-基)丙-2-烯-1-酮之磷酸鹽、其結晶形式及其製備方法
US11267805B2 (en) Solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl) piperazine-1-yl)(1-hydroxycyclopropyl)methanone
JP2020535192A (ja) レナリドミドの結晶形
EP3634972A2 (fr) Procédés perfectionnés de préparation de guadécitabine et d'intermédiaires de celle-ci
KR20250085608A (ko) 1-((3S,4R)-3-((2-((1-에틸-1H-피라졸-4-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)옥시)-4-플루오로피페리딘-1-일)프로프-2-엔-1-온의인산염, 이의 결정형 및 이의 제조 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16711484

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16711484

Country of ref document: EP

Kind code of ref document: A1